Revision of the criteria for Alzheimer's disease: A symposium

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Alzheimer's & Dementia

• Publication date

  2011-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jalz.2010.12.007PMID 21322828
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnostic and Statistical Manual of Mental Disorders

  2013cited by this paper
• Conclusions and next steps.

  2011cited by this paper
• Association between GAB2 haplotype and higher glucose metabolism in Alzheimer's disease-affected brain regions in cognitively normal APOEε4 carriers

  2011cited by this paper
• Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

  2011cited by this paper
• Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

  2010influential reference
• EFNS guidelines for the diagnosis and management of Alzheimer’s disease

  2010cited by this paper
• Comparing predictors of conversion and decline in mild cognitive impairment

  2010cited by this paper
• Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

  2010cited by this paper
• Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.

  2010cited by this paper
• Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

  2010cited by this paper
• Use of Genetic Variation as Biomarkers for Mild Cognitive Impairment and Progression of Mild Cognitive Impairment to Dementia

  2010cited by this paper
• In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia

  2010cited by this paper
• Where Vascular Meets Neurodegenerative Disease

  2010cited by this paper
• Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.

  2009cited by this paper
• Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts.

  2009cited by this paper
• Amyloid + activation = Alzheimer's?

  2009cited by this paper
• Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly

  2009cited by this paper
• A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease

  2009cited by this paper
• Mild cognitive impairment: ten years later.

  2009cited by this paper
• Lewy Body Variant of Alzheimer's Disease: Selective Neocortical Loss of t-SNARE Proteins and Loss of MAP2 and α-Synuclein in Medial Temporal Lobe

  2009cited by this paper
• Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment

  2009cited by this paper
• Longitudinal study of the transition from healthy aging to Alzheimer disease.

  2009cited by this paper
• MRI and CSF biomarkers in normal, MCI, and AD subjects

  2009cited by this paper
• Use of Genetic Variation as Biomarkers for Alzheimer's Disease

  2009cited by this paper
• Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

  2009cited by this paper
• Faculty Opinions recommendation of Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

  2009cited by this paper
• Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients.

  2009cited by this paper
• Preclinical Properties of 18F-AV-45: A PET Agent for Aβ Plaques in the Brain

  2009cited by this paper
• CSF Biomarkers

  2009cited by this paper
• PET imaging of amyloid deposition in patients with mild cognitive impairment.

  2008cited by this paper
• Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

  2008cited by this paper
• Hippocampal hypometabolism predicts cognitive decline from normal aging.

  2008cited by this paper
• Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.

  2008cited by this paper
• Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease

  2008cited by this paper
• Functional interactions of APP with the apoE receptor family

  2008cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders

  2008cited by this paper
• MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study.

  2008cited by this paper
• Safety and efficacy of galantamine in subjects with mild cognitive impairment

  2008cited by this paper
• Molecular genetics of Alzheimer's disease: An update

  2008cited by this paper
• Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study

  2008cited by this paper
• CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer’s disease

  2008cited by this paper
• Amyloid, hypometabolism, and cognition in Alzheimer disease

  2007cited by this paper
• CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.

  2007cited by this paper
• Imaging beta-amyloid burden in aging and dementia.

  2007cited by this paper
• Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.

  2007cited by this paper
• Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases

  2007cited by this paper
• Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.

  2007cited by this paper
• Application of automated medial temporal lobe atrophy scale to Alzheimer disease.

  2007cited by this paper
• Neuropsychiatric symptoms (behavioral and psychological symptoms of dementia) and the development of dementia treatments

  2007cited by this paper
• Mixed brain pathologies account for most dementia cases in community-dwelling older persons

  2007cited by this paper
• Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

  2007cited by this paper
• Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.

  2007cited by this paper
• Potential antecedent marker of Alzheimer disease

  2006cited by this paper
• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

  2006influential reference
• [11C]PIB in a nondemented population

  2006cited by this paper
• Neuropathology of older persons without cognitive impairment from two community-based studies

  2006cited by this paper
• Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people.

  2006cited by this paper
• Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

  2005cited by this paper
• Vitamin E and donepezil for the treatment of mild cognitive impairment.

  2005cited by this paper
• A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment

  2005cited by this paper
• A synopsis of the practice parameters on dementia from the american academy of neurology on the diagnosis of dementia.

  2004cited by this paper
• Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.

  2004cited by this paper
• More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases.

  2004cited by this paper
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

  2004cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy.

  2003cited by this paper
• Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

  2003cited by this paper
• Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients.

  2003cited by this paper
• Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. The Standards for Reporting of Diagnostic Accuracy Group.

  2003cited by this paper
• Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative

  2003cited by this paper
• Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion.

  2002cited by this paper
• Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  2002cited by this paper
• Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET)

  2001cited by this paper
• Barriers to Treatment: The Unique Challenges for Physicians Providing Dementia Care

  2001cited by this paper
• Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry

  2000cited by this paper
• Handbook of Psychiatric Measures

  2000cited by this paper
• Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

  2000cited by this paper
• Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies.

  1997cited by this paper
• Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

  1997cited by this paper
• The challenge of characterizing normal brain aging in relation to Alzheimer's disease.

  1997cited by this paper
• Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

  1995cited by this paper
• Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

  1993cited by this paper
• Morphometric image analysis of neuropil threads in Alzheimer's disease.

  1993cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1991cited by this paper
• Global Deterioration Scale (GDS).

  1988cited by this paper
• Diagnosis of Alzheimer's disease.

  1988cited by this paper
• Diagnosis of Alzheimer's disease.

  1985cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• A New Clinical Scale for the Staging of Dementia

  1982cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Measuring Sense of Agency in Neurodegenerative Dementias: Evidence From the Intentional Binding Effect.

  2026cites this paper
• The role of the Alzheimer's Association in the genesis of Alzheimer's Disease Neuroimaging Initiative

  2024cites this paper
• Diagnosi clinicolaboratoristica della malattia di Alzheimer

  2021cites this paper
• Role of Salvia officinalis Silver Nanoparticles in Attenuation Renal Damage in Rabbits Exposed to Methotrexate.

  2021cites this paper
• Diagnostic clinicobiologique de la maladie d’Alzheimer

  2021cites this paper
• Depresión en el anciano, síntomas psicológicos y conductuales asociados a la demencia y síndrome paraneoplásico: dificultades diagnósticas. A propósito de un caso

  2020cites this paper
• Measuring hippocampal neuroanatomical asymmetry to better diagnose Alzheimer's disease

  2019cites this paper
• The Iraqi Journal of Veterinary Medicine, 42(2):7-20

  2019cites this paper
• Multi-Objective Genetic Algorithms to Find Most Relevant Volumes of the Brain Related to Alzheimer's Disease and Mild Cognitive Impairment

  2018cites this paper
• Neurodegenerative Protein Misfolding Disorders and the Skin

  2018cites this paper
• ON BIOMARKER AND ITS POTENTIAL APPLICATIONS

  2017cites this paper
• Hypertension is associated with worse cognitive function and hippocampal hypometabolism in Alzheimer's disease

  2017cites this paper
• POSIBLES RELACIONES ENTRE ENFERMEDAD DE ALZHEIMER, INSULINORRESISTENCIA Y DIABETES MELLITUS TIPO 2

  2017cites this paper
• Pharmacotherapy of Dementia

  2016cites this paper
• Développement de méthodes de référence pour spectrométrie de masse pour le dosage de biomarqueurs de la maladie d'Alzheimer

  2016cites this paper
• Peer Reviewed Title: D-serine levels in Alzheimer's disease: Implications for novel biomarker development

  2015cites this paper
• Características psicométricas das versões completa e reduzida do IQCODE-BR em idosos de baixa renda e escolaridade

  2015cites this paper
• Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applications

  2015cites this paper
• Alzheimer's disease research in the context of the national plan to address Alzheimer's disease.

  2015cites this paper
• Corpus Callosum Structure is Topographically Correlated with the Early Course of Cognition and Depression in Alzheimer's Disease

  2015cites this paper
• Fluorodeoxiglucose positron emission tomography (FDG- PET) in the diagnosis of mild to moderate dementia

  2015cites this paper
• Sulcal morphology as a new imaging marker for the diagnosis of early onset Alzheimer's disease.

  2015cites this paper
• d-serine levels in Alzheimer's disease: implications for novel biomarker development

  2015cites this paper
• The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding

  2015cites this paper
• Caspases: Therapeutic Targets in Neurologic Disease

  2014cites this paper
• A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles

  2014cites this paper
• Evaluation of cognitive performance within the disease course of Alzheimer´s

  2014cites this paper
• La aplicación de biomarcadores a la búsqueda de nuevas farmacoterapias para el tratamiento de la enfermedad de Alzheimer

  2014cites this paper
• Diagnosticare la malattia di Alzheimer

  2014cites this paper
• Requirements Elicitation and System Specification of Assistive Systems for People with Mild Dementia

  2013influential citation
• Evaluation of cognitive performance within the disease course of Alzheimers

  2013cites this paper
• Clinical implications of the new diagnostic guidelines for dementia.

  2013cites this paper
• Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress.

  2013cites this paper
• Transformations in Health Policy: An Analysis of Alzheimer's Disease Testing, Medicaid Enrollment, and Insurance Market Concentration

  2013cites this paper
• Diagnostiquer la maladie d’Alzheimer

  2013cites this paper
• Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease

  2013cites this paper
• Perspectives in Molecular Imaging Using Staging Biomarkers and Immunotherapies in Alzheimer's Disease

  2013cites this paper
• Alzheimer's Disease Diagnosis and Management

  2013cites this paper
• Clinical and research diagnostic criteria for Alzheimer's disease.

  2012cites this paper
• No se puede tapar el sol con las manos… Nuevos criterios diagnósticos en la enfermedad de Alzheimer

  2012cites this paper
• No se puede tapar el sol con las manos. . . Nuevos criterios diagnósticos en la enfermedad de Alzheimer

  2012cites this paper
• The Current Status of Alzheimer's Disease Treatment

  2012cites this paper
• Should Alzheimer's disease be equated with human brain ageing? A maladaptive interaction between brain evolution and senescence.

  2012cites this paper
• Contributions of Brain Insulin Resistance and Deficiency in Amyloid-Related Neurodegeneration in Alzheimer’s Disease

  2012cites this paper
• Putting Dementia into Context - A Selective Literature Review of Assistive Applications for Users with Dementia and Their Caregivers

  2012cites this paper
• Epidemiology of cognitive aging and Alzheimer's disease: contributions of the cache county utah study of memory, health and aging.

  2012cites this paper
• Biomarker discovery for sparse classification of brain images in Alzheimer's disease

  2012cites this paper
• Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease.

  2012cites this paper
• Alzheimer's Disease and the “Valley of Death”: Not Enough Guidance from Human Brain Tissue?

  2012cites this paper
• Behavioral Neurobiology of Aging

  2012cites this paper
• Current and Emerging Drug Treatment Options for Alzheimer’s Disease

  2011cites this paper
• PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease

  2011cites this paper
• Memantine: a treatment for Alzheimer's disease with a new formulation

  2011cites this paper
• Biomarkers for cognitive decline: opportunities and challenges.

  2011cites this paper
• Fast Brain-Wide Search of Highly Discriminative Regions in Medical Images: an Application to Alzheimers Disease

  2011cites this paper